Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (Feb 17, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 17, 2026
Period End
February 17, 2026
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Nov ’19Nov ’19
  3. Leadership change8-K · Feb ’23Feb ’23
  4. Leadership change8-K · Mar ’25Mar ’25

Summary

Summary of the 8-K filed February 17, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release under Item 2.02 reporting fourth-quarter and full-year 2025 results.

Full-year total revenue was $1,396.6 milliona, up 38% from $1,015.3 million in 2024, driven by royalty revenue of $867.8 million (up 52% from $571.0 million) and higher product sales. Net income for the full year was $316.9 million, compared with $444.1 million in 2024. The results include $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition, which drove a fourth-quarter net loss of $141.6 million.

Fourth-quarter total revenue was $451.8 millionb, up 52% from $298.0 million. Full-year GAAP diluted EPS was $2.56 versus $3.43 in 2024, and non-GAAP diluted EPS was $4.15 versus $4.23. The company reported that cash, cash equivalents, restricted cash and marketable securities were $145.4 million at December 31, 2025, compared with $596.1 million a year earlier, mainly reflecting cash used for the Elektrofi and Surf Bio acquisitions and share repurchases, partly offset by net proceeds from $1.5 billion of convertible notes issued in November 2025 (two $750.0 million tranches due 2031 and 2032).

The company also amended its credit agreement, raising its revolving facility from $575.0 million to $750.0 millionc. Halozyme reiterated its 2026 guidance: total revenue of $1.710 to $1.810 billion (22% to 30% growth), royalty revenue of $1.130 to $1.170 billion (30% to 35% growth), adjusted EBITDA of $1.125 to $1.205 billion (71% to 83% growth), and non-GAAP diluted EPS of $7.75 to $8.25 (87% to 99% growth).

The guidance includes approximately $60 milliond of investment related to Hypercon and Surf Bio. Management stated it expects royalty revenue to exceed $1 billion in 2026 and has a "clear line of sight" to more than $2 billion in total revenue by 2028.

Key Highlights

  1. Full-year 2025 total revenue rose 38% to a record $1,396.6 million; royalty revenue rose 52% to $867.8 million.
  2. Fourth-quarter 2025 total revenue was $451.8 million, up 52% from $298.0 million a year earlier.
  3. Fourth-quarter net loss of $141.6 million included $284.9 million of acquired IPR&D expense from the Surf Bio acquisition; full-year GAAP diluted EPS was $2.56 versus $3.43 in 2024.
  4. Full-year adjusted EBITDA was $657.6 million versus $632.2 million in 2024; fourth-quarter adjusted EBITDA was $21.9 million versus $195.8 million, and the Surf Bio IPR&D charge was included in adjusted EBITDA.
  5. Cash and marketable securities fell to $145.4 million from $596.1 million, after the Elektrofi and Surf Bio acquisitions and share repurchases.
  6. The company issued $750.0 million of 2031 and $750.0 million of 2032 convertible notes in November 2025 and raised its revolving credit facility to $750.0 million from $575.0 million.
  7. 2026 guidance was reiterated: total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, adjusted EBITDA of $1.125 to $1.205 billion, and non-GAAP diluted EPS of $7.75 to $8.25.

Frequently Asked Questions

  1. What drove the growth in Halozyme's 2025 revenue?

    Total revenue increased 38% to $1,396.6 million, primarily from royalty revenue growth and higher product sales. Royalties rose 52% to $867.8 million, driven mainly by sales uptake of ENHANZE partner products launched since 2020, predominantly VYVGART Hytrulo by argenx, DARZALEX SC by Janssen and Phesgo by Roche.

  2. Why was the fourth-quarter 2025 result a net loss?

    The fourth-quarter net loss of $141.6 million included $284.9 million of acquired in-process R&D expense related to the Surf Bio acquisition, which the filing says reduced GAAP diluted EPS by $2.42 in the quarter. The company did not exclude this expense from its non-GAAP results.

  3. What is the company's 2026 outlook?

    Halozyme reiterated guidance for total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, adjusted EBITDA of $1.125 to $1.205 billion, and non-GAAP diluted EPS of $7.75 to $8.25. The guidance includes approximately $60 million of new Hypercon and Surf Bio investment and does not reflect potential future share repurchases.

  4. How did Halozyme change its capital structure in 2025?

    In November 2025, the company sold $750.0 million of 2031 convertible notes and $750.0 million of 2032 convertible notes, using part of the proceeds for capped call transactions and for privately negotiated repurchases of some 2027 and 2028 convertible notes. It also amended its credit agreement to extend maturity and increase the revolving facility from $575.0 million to $750.0 million.

  5. What are the company's longer-term targets?

    CEO Dr. Helen Torley stated that royalty revenue is projected to exceed $1 billion in 2026 and that the company has a clear line of sight to more than $2 billion in total revenue by 2028. She also cited six projected new ENHANZE and two Hypercon development program starts and plans to sign three or more ENHANZE and Hypercon partnerships in 2026.